Boston Scientific (BSX) is on track to be the highest performing large cap medtech company, RBC Capital Markets said in a note emailed Friday.
The firm said it had come away more bullish on the company's 2025 setup after catching up with the company and its investors.
The firm cited the company's diversified portfolio and category leadership, as well as pipeline initiatives, as reasons to be positioned attractively in 2025.
RBC Capital also said the company's 2025 guidance was "prudent and achievable," but one that it is positioned to beat and raise from.
The firm has an outperform rating on the stock with a price target of $105.
Price: 98.76, Change: +0.59, Percent Change: +0.60
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.